Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (148)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Green, M. D.
Right arrow Articles by Piccart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, M. D.
Right arrow Articles by Piccart, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:29-35, 2003
© 2003 European Society for Medical Oncology

Original Paper

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

M. D. Green1,+, H. Koelbl2, J. Baselga3, A. Galid4, V. Guillem5, P. Gascon6, S. Siena7, R. I. Lalisang8, H. Samonigg9, M. R. Clemens10, V. Zani11, B. C. Liang11, J. Renwick11 and M. J. Piccart On behalf of the International Pegfilgrastim 749 Study Group12,§

1 Royal Melbourne and Western Hospitals, Melbourne, Australia; 2 Martin Luther University, Halle-Wittenberg, Germany; 3 Hospital Vall d’Hebron, Barcelona, Spain; 4 Universitaetsklinik fuer Frauenheilkunde, Vienna, Austria; 5 Instituto Valenciano de Oncologia, Valencia, Spain; 6 Hospital Clinic, Barcelona, Spain; 7 Ospedale Niguarda Ca’ Granda, Milan, Italy; 8 Academisch Ziekenhuis Maastricht, Maastricht, The Netherlands; 9 Medizinische Universitaetsklinik, Graz, Austria; 10 Krankenanstalt Mutterhaus der Borromaerinnen, Trier, Germany; 11 Amgen Inc, Thousand Oaks, CA, USA; 12 Institut Jules Bordet, Brussels, Belgium

Received 20 March 2002; revised 3 June 2002; accepted 17 July 2002

Background:

We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support.

Patients and methods:

Patients (n = 157) were randomized to receive either a single 6 mg subcutaneous (s.c.) injection of pegfilgrastim or daily 5 mg/kg s.c. injections of filgrastim, after doxorubicin and docetaxel chemotherapy (60 mg/m2 and 75 mg/m2, respectively). Duration of grade 4 neutropenia, depth of neutrophil nadir, incidence of febrile neutropenia, time to neutrophil recovery and safety information were recorded.

Results:

A single 6 mg injection of pegfilgrastim was as effective as daily injections of filgrastim for all efficacy measures for all cycles. The mean duration of grade 4 neutropenia in cycle 1 was 1.8 and 1.6 days for the pegfilgrastim and filgrastim groups, respectively. Results for all efficacy end points in cycles 2–4 were consistent with the results from cycle 1. A trend towards a lower incidence of febrile neutropenia was noted across all cycles with pegfilgrastim compared with filgrastim (13% versus 20%, respectively). A single fixed dose of pegfilgrastim was as safe and well tolerated as standard daily filgrastim.

Conclusions:

A single fixed dose of pegfilgrastim administered once per cycle of chemotherapy was comparable to multiple daily injections of filgrastim in safely providing neutrophil support during myelosuppressive chemotherapy. Pegfilgrastim may have utility in other clinical settings of neutropenia.

Key words: breast cancer, clinical trial, hemopoietic growth factor, multicenter study, neutropenia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
P. Gascon, U. Fuhr, F. Sorgel, M. Kinzig-Schippers, A. Makhson, S. Balser, S. Einmahl, and M. Muenzberg
Development of a new G-CSF product based on biosimilarity assessment
Ann. Onc., December 17, 2009; (2009) mdp574v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Castagna, S. Bramanti, A. Levis, M. G. Michieli, A. Anastasia, R. Mazza, L. Giordano, B. Sarina, E. Todisco, A. I. Gregorini, et al.
Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support
Ann. Onc., December 11, 2009; (2009) mdp576v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Fox, B. C. Widemann, D. S. Hawkins, N. Jayaprakash, R. Dagher, A. A. Aikin, D. Bernstein, L. Long, C. Mackall, L. Helman, et al.
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clin. Cancer Res., December 1, 2009; 15(23): 7361 - 7367.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Yamamoto, I. Sekine, K. Nakagawa, M. Takada, M. Fukuoka, Y. Tanigawara, and N. Saijo
A Pharmacokinetic and Dose Escalation Study of Pegfilgrastim (KRN125) in Lung Cancer Patients with Chemotherapy-induced Neutropenia
Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 425 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Crawford, C. Caserta, F. Roila, and On behalf of the ESMO Guidelines Working Group
Hematopoietic growth factors: ESMO Recommendations for the applications
Ann. Onc., May 1, 2009; 20(suppl_4): iv162 - iv165.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Moreau, J. Klastersky, A. Schwarzbold, F. Muanza, A. Georgala, M. Aoun, A. Loizidou, M. Barette, S. Costantini, M. Delmelle, et al.
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
Ann. Onc., March 1, 2009; 20(3): 513 - 519.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B.-B. Yang, A. Kido, M. Salfi, S. Swan, and J. T. Sullivan
Pharmacokinetics and Pharmacodynamics of Pegfilgrastim in Subjects With Various Degrees of Renal Function
J. Clin. Pharmacol., September 1, 2008; 48(9): 1025 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Ishiguro, T. Kitano, H. Yoshibayashi, M. Toi, T. Ueno, H. Yasuda, K. Yanagihara, C. L. Garbo, and M. Fukushima
Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim
Ann. Onc., May 1, 2008; 19(5): 1019 - 1019.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. Piedbois, D. Serin, F. Priou, P. Laplaige, J.-F. Berdah, and J. Grenier
Reply to Letter to the editor, by Ishiguro et al. (Ann Oncol)
Ann. Onc., May 1, 2008; 19(5): 1019 - 1020.
[Full Text] [PDF]

Home page
 haematolHome page
N. Russell, R. Mesters, J. Schubert, M. Boogaerts, H. E. Johnsen, C. d. Canizo, N. Baker, P. Barker, T. Skacel, and N. Schmitz
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy
Haematologica, March 1, 2008; 93(3): 405 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. von Minckwitz, S. Kummel, A. du Bois, W. Eiermann, H. Eidtmann, B. Gerber, J. Hilfrich, J. Huober, S. D. Costa, C. Jackisch, et al.
Pegfilgrastim {+/-} ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
Ann. Onc., February 1, 2008; 19(2): 292 - 298.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. M. R. Choi, C. Guelcher, and M. F. Guerrera
Novel treatment for severe congenital neutropenia with pegfilgrastim
Blood, December 1, 2007; 110(12): 4134 - 4134.
[Full Text] [PDF]

Home page
 The OncologistHome page
H. Ozer, B. Mirtsching, M. Rader, S. Luedke, S. J. Noga, B. Ding, and L. Dreiling
Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
Oncologist, April 1, 2007; 12(4): 484 - 494.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. N.H. Timmer-Bonte, E. M.M. Adang, H. J.M. Smit, B. Biesma, F. A. Wilschut, G. P. Bootsma, T. M. de Boo, and V. C.G. Tjan-Heijnen
Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2006; 24(19): 2991 - 2997.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. K. Roskos, P. Lum, P. Lockbaum, G. Schwab, and B.-B. Yang
Pharmacokinetic/Pharmacodynamic modeling of pegfilgrastim in healthy subjects.
J. Clin. Pharmacol., July 1, 2006; 46(7): 747 - 757.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, T. Ishimori, J. M. Engles, S. Leboulleux, V. Stearns, and R. L. Wahl
Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies
J. Nucl. Med., June 1, 2006; 47(6): 950 - 956.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
L. Spina and E. Besa
Granulocyte Colony-Stimulating Factor Induced Differentiation Syndrome Mimicking Acute Myeloid Leukemia and the Unmasking of Chronic Myelomonocytic Leukemia.
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4428 - 4428.
[Abstract]

Home page
 JCOHome page
P. Papaldo, M. Lopez, P. Marolla, E. Cortesi, M. Antimi, E. Terzoli, P. Vici, C. Barone, G. Ferretti, S. Di Cosimo, et al.
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
J. Clin. Oncol., October 1, 2005; 23(28): 6908 - 6918.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. A. Gregory and L. Trumper
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Ann. Onc., September 1, 2005; 16(9): 1413 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. H. Lyman, C. H. Lyman, O. Agboola, and for the Anc Study Group
Risk Models for Predicting Chemotherapy-Induced Neutropenia
Oncologist, June 1, 2005; 10(6): 427 - 437.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Vogel, M. Z. Wojtukiewicz, R. R. Carroll, S. A. Tjulandin, L. J. Barajas-Figueroa, B. L. Wiens, T. A. Neumann, and L. S. Schwartzberg
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
J. Clin. Oncol., February 20, 2005; 23(6): 1178 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
B. L Stanford, S. D Zondor, and E. Cobos
Is pegfilgrastim appropriate for the treatment of established febrile neutropenia?
Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 113 - 119.
[Abstract] [PDF]

Home page
 Ann OncolHome page
J. Crawford
Pegfilgrastim: the promise of pegylation fulfilled
Ann. Onc., January 1, 2003; 14(1): 6 - 7.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.